Six Questions For Janssen Pharma Chairman Paul Stoffels
This article was originally published in The Pink Sheet Daily
Executive Summary
Amid increasing competition, the need is to be the best in collaboration with academics, and not to rely on a single regulatory agency amid regulatory delays in China, stresses Johnson & Johnson senior executive Paul Stoffels in a wide-ranging exclusive interview with PharmAsia News.
You may also be interested in...
Backing New Index Fund, GSK, J&J Buy Into Asset-Centric Vision Of Biotech Future
Index Life VI is the first life-sciences-only fund for Index; GSK’s Moncef Slaoui and J&J’s Paul Stoffels are on scientific advisory board.
China Hits Two Billion COVID Jabs But More Effective mRNA Shots Elude
Despite administering a total of 2.2 billion COVID-19 shots, China as the first country to experience the coronavirus outbreak has yet to open its borders, while more effective mRNA vaccines are still nowhere to be found amid apparent delays for the licensed-in lead candidate.
Emerging Biopharma’s Next First Launch Market: China?
Despite multiple challenges including pricing pressures and slowing general economic growth, China offers attractive opportunities for emerging biopharma firms, helped by an encouraging regulatory environment. But weighing up options around challenging areas including partnering is essential, a new report states.